Unknown PHASE2 INTERVENTIONAL 4-arm NCT00502021

Use of Flaxseed(Alpha Linolenic Acid) Powder in Morbidly Obese Patients With Systemic Inflammation

Inflammatory Indicators and Arterial Stiffness in Patients With Severe Obesity. Response to Supplementation of Alpha Linolenic Acid

Sponsor: University of Sao Paulo

Conditions Atherosclerosis Morbid Obesity Systemic Inflammation

Interventions Alpha linolenic acid/ALA Alpha-linolenic acid/ALA Placebo

Updated 6 times since 2017 Last updated: Sep 27, 2012 Started: Aug 31, 2007 Primary completion: Aug 31, 2013 Completion: Oct 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Atherosclerosis and Morbid Obesity, this trial is ongoing. The trial is conducted by University of Sao Paulo and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Sao Paulo

Data source: University of Sao Paulo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil